Continous Infusion of Nefopam for Patients Undergoing Pancreatoduodenectomy

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-80
SponsorIuliu Hatieganu University of Medicine and Pharmacy

About this trial

The goal of this clinical trial is to determine whether continuous nefopam administration, as part of a multimodal analgesia strategy, reduces opioid consumption and improves patient satisfaction after pancreatoduodenectomy.

The main questions are:

Does nefopam administration reduce opioid consumption after pancreatoduodenectomy?

Does nefopam administration reduce postoperative pain levels after pancreatoduodenectomy?

Researchers will compare two other analgesic strategies, namely continuous lidocaine infusion and epidural analgesia, to assess whether they lead to better outcomes.

Participants will complete the QoR-15 questionnaire and report their pain levels at predefined time points before and after surgery.

Eligibility criteria

Qualifiers

Patients scheduled for elective pancreatoduodenectomy surgery

Agreed to participate in the study

Disqualifiers

Refusal to participate

Emergency surgery

Patients with neurological disorders or other muscular or psychiatric disorders that impede communication

Known allergic reactions to the used medication

Trial design

Treatments tested in this trial

  • Nefopam 120mg/day infusion
  • Lidocaine Infusion
  • Peridural
  • Multimodal IV analgesia

Treatment groups

93 Participants
are divided into 3 treatment groups